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Abstract
Introduction. Human Beta Defensin-1 (hBD-1) is a component of the innate
immune system, the first line of defence against pathogens, already reported
as involved in the susceptibility to HIV-1 infection and HIV-1 mother-to-child
transmission (MTCT) in different populations. 
We investigated the role of DEFB1gene (encoding for hBD-1) functional
polymorphisms in the susceptibility to HIV-1 MTCT in a population from
Zambia.
Methods. Four selected polymorphisms within DEFB1 gene, three at the
5' untranslated region (UTR), namely –52G>A (rs1799946), –44C>G
(rs1800972) and –20G>A (rs11362) and one in the 3’UTR, c.*87A>G
(rs1800972), were genotyped in 101 HIV-1 positive mothers (26 transmitters
– 27% and 75 not transmitters – 73%) and 331 infants born to HIV-1 infected
mothers (85 HIV-1 positive - 26% and 246 exposed but not infected – 74%).
Results. DEFB1 c.*87 A allele was more frequent among HIV- children
respect to HIV+ (with intra-uterine MTCT). Concerning DEFB1haplotypes,
GCGA haplotype resulted more represented in HIV- than HIV+ infants and
DEFB1ACGG haplotype presented increased frequency in HIV- children
respect to HIV+ (with intra-partum MTCT) (p=0.02, p=0.002 and p= 0.006
respectively).
Conclusion. DEFB1 polymorphisms were significantly associated with
decreased risk of HIV-1 infection acquisition in the studied Zambian
population suggesting that they may play a role in HIV-1 MTCT.
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Introduction
Human immunodeficiency type-1 (HIV-1) mother-to-child transmission (MTCT)
has been dramatically reduced with the introduction of HIV test in all pregnant
women and consequent antiretroviral drugs administration in those positive for
virus infection; also alternative to breastfeeding and caesarean partum contributed
to prevent MTCT [1]. Nevertheless, data from past years in which antiretroviral
drugs were not yet available for prevention provide a unique model to understand
the role of host genetic factors in the modulation of HIV-1 infection susceptibility, a
multifactorial trait [2].
So far several genes and genetic polymorphisms (e.g. single nucleotide
polymorphisms, SNPs) have been described as conferring risk or protection towards
HIV-1 infection [3]. Since innate immunity is known to play a crucial role in
the immune system of the foetus, we focused our attention on functional genetic
variations distributed in primary natural defence genes. Therefore, we studied DEFB1
(8p23.1) gene encoding for the human beta defensins 1 (hBD-1), an antimicrobial
peptide [4], known for its antimicrobial properties against bacteria, fungi but also
viruses [5] and already investigated in the context of HIV-1 MTCT [6, 7, 8, 9].
DEFB1 expression has been detected in the placenta, and a role in the protection
against HIV-1 mother-to-foetus transmission has been hypothesized [9].
DEFB1 gene presents different functional polymorphisms, the –52G>A (rs1799946),
–44C>G (rs1800972) and –20G>A (rs11362) at the 5' untranslated region (5'UTR)
and c.*87A>G (rs1800971) at the 3’UTR possibly modulating DEFB1 gene
expression in different cellular models [10, 11, 12, 13].
In this study, taking into account the previously reported role of DEFB1 genetic
variations in the context of HIV-1 infection, we analysed the four above-mentioned
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DEFB1 functional polymorphisms in 101 HIV-1 positive mothers and 331 infants
born to HIV-1-positive mothers from Zambia with the aim of investigating their
potential impact in the susceptibility to HIV-1 perinatal infection.
Material and Methods
Study population
The Zambia Exclusive Breastfeeding Study (ZEBS, Lusaka Zambia,
ClinicalTrials.gov Identifier: NCT00310726) population recruited for this study was
previously analysed in another work by Segat et al. [14]: briefly the ZEBS was a
randomized clinical trial that investigated if exclusive breastfeeding up to 4 months
could reduce the risk of HIV-1 transmission respect to longer breastfeeding through
a median of 16 months. Nine hundred and fifty-eight HIV-1 positive women were
enrolled during pregnancy at two prenatal care clinics (May 2001 to September 2004),
and they were followed to delivery and 24 months post partum with their infants who
were tested regularly for HIV. All women were counseled to breastfeed to at least
4 months, then, half of the women were randomized to stop all breastfeeding and
the other half to continue breastfeeding for as long as they usually would. Detailed
information is provided in table supplementary 1.
For the current genetic analysis 331 infants were selected: 85 were HIV-1 infected
(designed as HIV+): 22 (6.9%) had intrauterine MTCT (IU - defined as a positive
polymerase chain reaction (PCR) result within 2 days of birth), 25 (7.5%) had
intrapartum MTCT (IP - defined as a positive PCR result within 42 days of birth with
an earlier negative result) and 38 (14.4%) had postnatal (breastfeeding) MTCT (PP
- defined as a positive PCR results older than 42 days with a negative earlier result
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in a breastfed child). The remainder 246 were HIV-1-exposed uninfected children
(designed as HIV-). The samples of 101 available HIV-1 positive mothers (mean age
26 years, range 18-45) of these children were selected and included in the genotyping
analysis: 26 of these transmitted the HIV-1 infection to their newborns (designed as
TR): 26.9% (7/26) were IU trnsmitted MTCT, 30.8% (8/26) were IP transmitted, and
42.3% (11/26) were PP transmitted via breastfeeding; 75 mothers did not transmit
HIV-1 to their infants (designed as NTR). The numbers of enrolled children and
mother is different since a subset of 331 out of 632 infants and 101 mothers out of
958 recruited in the trial had available dried blood spot specimen useful for DNA
extraction and subsequent genotyping. 
All women provided written informed consent for participating in the study. All the
study experiments and procedures have been performed in accordance with ethical
standards of the 1975 Declaration of Helsinki (7th revision, 2013) and the ethical
committee of IRCCS Burlo Garofolo approved the study (protocol L-1106, 1 May
2010).
DEFB1 genotyping
DNA extraction was performed from dried blood spots as described in Segat et al.
[14]. The four polymorphisms at DEFB1 gene were detected using TaqMan SNPs
genotyping assays and TaqMan® GTXpress™ Master Mix on the ABI7900HT
Real Time PCR platform (Applied Biosystems - Life Technologies, Carlsbad,
California, U.S.A.), following manufacturer instructions: DEFB1 5'UTR -52G>A
(rs1799946), -44C>G (rs1800972), -20G>A (rs11362) and 3’UTR c.*87A>G
(rs1800971) polymorphisms using respectively C__11636795_20, C__11636794_10,
C__11636793_20 and C___8845559_10 assays.
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Statistical analysis
DEFB1allele and genotype frequencies were calculated by direct counting, while
haplotype frequencies and linkage disequilibrium were computed using the Arlequin
software version 3.5.1.2 [15]. 
Nonparametric Wilcoxon rank sum test with continuity correction were used to
compare continuous variables. Fisher’s exact test was used for pairwise comparison
of allele, genotype and haplotype frequencies. Logistic regression and Wald’s test
were conducted to examine the association between polymorphisms genotypes and
the risk of HIV-1 MTCT. The statistical tests were performed with the free software
R version 3.1.3 [16]. P-value for linkage disequilibrium analysis was calculated
using the permutation test with the EM algorithm, on Arlequin [15], whereas D’ and
r2 measures were computed with SNPstat [17]. Post-hoc power calculations were
performed with G*Power software version 3.1.9.2 using post-hoc calculation using
Fisher’s exact test [18].
Results
HIV-1 MTCT status significantly correlated with maternal CD4 cells count and
plasma viral load (Wilcoxon rank sum test with continuity correction p=3.544e-08 and
p=2.35e-13 respectively) (table supplementary 1).
DEFB1 polymorphisms at position -52G>A, -44C>G and -20G>A were in Hardy
Weinberg equilibrium (HWE) in all groups (both of mothers and children) with
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the exception of the -44C>G variation in HIV- children group (table 1, 2 and
supplementary table 2). The polymorphisms were in linkage disequilibrium in the
children but not in the mothers (D’>0.51, r2>0.01, p<0.04 and D’>0.645, r2>0.02,
p<0.07 respectively) and combined to form three major haplotypes, namely ACGA,
GCAA, ACGG and other minor haplotypes (with frequency <0.05).
Analysing DEFB1 polymorphisms’ allele and genotype frequency distribution no
statistical significant differences were observed between HIV+ and HIV- children,
also when stratifying for HIV-1 routes of MTCT (table 1, table 2). An exception was
the c.*87 G allele, more frequent among IU HIV+ and associated with increased risk
of IU HIV-1 MTCT (p=0.02, OR=2.09, CI=1.05-4.10, power=0.57; table 2).
When DEFB1 haplotypes were considered, the GCGA haplotype was significantly
more frequent among HIV- children than ACGA more represented in HIV+
and associated with protection towards HIV-1 infection (p=0.002; OR=0.18;
CI=0.03-0.61; power: 0.93; table 1). When children were stratified according to
HIV-1 route of MTCT the ACGG haplotype was more represented among HIV-
respect to the ACGA haplotype, more frequent among IP HIV+, and associated with a
protection towards IP HIV-1 MTCT (p=0.006 OR= 0.23; CI=0.06-0.70; power: 0.80
table 2).
No statistical significant association was detected between maternal DEFB1
polymorphisms and the risk of HIV-1 MTCT, comparing NTR and TR mothers (table
supplementary 1).
Finally no association was found between the maternal DEFB1polymorphisms’
genotypes and maternal plasma viral load (data not shown).
The mothers and children data were also stratified based on maternal CD4 cells
count and plasma viral load (CD4+cells count: cut off=350 cells/mm3; mothers
group (n=101): low=17-347 cells/mm3, high=350-925 cells/mm3; children’s mothers
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(n=331): low=17-349 cells/mm3, high=350-1207 cells/mm3; plasma viral load
cut off=50000 copies/ml; mothers group (n=101): low=399-48180 copies/ml,
high=50800-75001 copies/ml; children’s mothers (n=331): low=399-49748 copies/
ml, high=50291-75001 copies/ml. DEFB1polymorphisms frequencies were not
significantly different comparing HIV+ and HIV- children and also between TR and
NTR mothers (table supplementary 3 and 4 respectively).
Discussion
In our study we tested the possible association between functional variations at
DEFB1 gene and susceptibility to HIV-1 vertical transmission in mothers and
children from Zambia: specifically we analysed the frequency distributions of four
polymorphisms within DEFB1 gene comparing TR and NTR mothers and HIV-1
positive and negative children.
DEFB1 c.*87 A allele associated with decreased susceptibility towards IU HIV-1
MTCT; additionally considering DEFB1 haplotypes, the GCGA associated with
protection towards acquiring HIV-1 MTCT, moreover when the children were
stratified according to the route of virus MTCT, the ACGG haplotypes were
correlated with decreased IP HIV-1 MTCT susceptibility.
Other previous works showed associations between DEFB1 polymorphisms and
HIV-1 infection in other ethnic groups. In Italians (European Caucasian) the increased
HIV-1 infection susceptibility was associated with -44 C/C genotype [19, 20], with
-52 A allele [6] and with -52A/-44C haplotype [6] among children. Moreover, the
maternal -52G/G genotype and 52G/-44G haplotype were correlated with protection
against HIV-1 MTCT [6]. Instead, in Brazilians children the HIV-1 infection
susceptibility was associated with -52 A/A and -20 G/G genotype [10], although
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another work by Segat et al. did not highlight any statistically significant associations
[21].
Another study investigated the role of the 5’UTR DEFB1 polymorphisms in
seropositive mother and their infants comparing them with healthy women and their
newborns in a population from a Colombia, but no statistically significant different
polymorphism frequencies were observed between the two groups [9]. 
The differences between our findings respect to the previous studies cited above
could be explained based upon the different ethnic origin of the population analysed,
and considering the fact that in some studies the comparison has been conducted
between healthy subjects and HIV-1 infected individuals and not between exposed
un-infected and infected subjects; furthermore only our study considered the virus
route of transmission, while the others just reported general susceptibility to HIV-1
MTCT. Instead, for the 3’UTR c.*87A>G polymorphism this was the first study
that considered this genetic variant in the context of HIV-1 infection and reported its
association with the risk of MTCT.
Beta defensins are important mediators of innate mucosal defence against microbial
infection and are also known for their antiviral activities [22]. There are controversial
reports regarding DEFB1 expression in various fluid tissues or cell lines [11, 12, 23,
24, 25], nevertheless hBD-1 is constitutively expressed at the mucosa surface [22]
and, very important for HIV-1 MTCT, in the placenta [9]. On the other hand, recent
evidences suggested that hBD-1 could be also induced by virus infection in vitro and
in vivo[26], and also in conventional monocytes from HIV-1 infected patients in the
acute phase but not in the chronic stage [27]
Our study indicated that the four DEFB1 polymorphisms could be involved in the
HIV-1 infection susceptibility, suggesting also an additive and cooperative effect: it
is possible to speculate that the DEFB1 c.*87 G allele genotype and DEFB1 ACGA
haplotype, more frequent among HIV+ children might decrease mRNA DEFB1
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expression, consequently diminishing hBD-1 levels, thus leading to an increased
risk of acquiring HIV-1 infection. Indeed, a possible explanation of the 5’UTR
polymorphisms haplotypes effect as a post-transcriptional regulation was suggested:
haplotypes could impact on RNA folding and so on its expression as suggested
by previous works [23, 28]. Moreover, our results were supported by our previous
research [24], where the A/G genotype and DEFB1 ACGA haplotype were correlated
with low concentration of hBD-1 in saliva, although the samples were Italian healthy
controls.
We are aware of a limitation of our study since the lack of biological samples other
than dried blood spots used for DNA extraction, didn’t allow us to quantify hBD-1
protein to validate our hypothesis.
In our study DEFB1 polymorphisms were not correlated with maternal viral load
or CD4 cells count, however former works evidenced that -52 G/G genotype was
correlated with low levels of HIV-1 RNA in breast milk of Mozambican women [29].
Moreover, -52 G/G genotype and -44C/G genotype were associated with low plasma
HIV-1 RNA in Italian women [6]. The difference could be due to different states of
disease progression not specified in these studies. 
Despite the importance of subject’s genetic background, other major factors are
supposed to be involved in the susceptibility to the HIV-1 infection such as maternal
viral load, virus subtypes and advancement of immune deficiency status [30].
In agreement with previous research, in our study HIV-1 MTCT was associated with
low maternal CD4 cells count and high plasma viral load. Garcia et al. found high
HIV-1 RNA plasma levels associated with a significant risk of HIV-1 MTCT [31],
similarly in population maternal viral loads were significantly higher in transmitters
than in non-transmitters.Moreover, low maternal CD4 cells count correlated with
an increased risk of HIV-1 MTCT and this finding was in agreement with previous
studies [32].
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In spite of our positive findings, taken into account some deviations from HWE,
probably due to the low number of subjects present in some groups, and the medium
value of the power analysis, further studies should be necessary to clarify the role
of DEFB1 gene polymorphisms in the multifactorial trait HIV-1 MTCT, since
we just analysed the genome component of our samples not being available any
biological material other than dried blood spot, for the functional validation (i.e.
ELISA quantification of hBD1) of the associations observed, although as mentioned
above, our previous results [24] supported our current data.
Acknowledgements 
This work has been supported by RC08/17 grant from IRCCS Burlo Garofolo Trieste /
Ministry of Health (Italy). This study was supported in part by grants from the Eunice
Kennedy Shriver, National Institute of Child Health and Human Development (NICHD),
National Institutes of Health (NIH) (HD39611, HD40777, HD57617).
VP was recipient of fellowship from IRCCS Burlo Garofolo.
Conflict of interest
The authors declared no conflict of interest
JU
ST
 AC
CE
PT
ED
References
1. UNAIDS. Global AIDS Update 2016, http://www.unaids.org. 2016.
2. Singh KK, Spector SA. Host genetic determinants of human immunodeficiency
virus infection and disease progression in children. Pediatr Res. 2009;65:55R-63R.
3. Carrington M, Bashirova AA, McLaren PJ. On stand by: host genetics of HIV
control. AIDS. 2013;27:2831-9.
4. Liu L, Zhao C, Heng HH, Ganz T. The human beta-defensin-1 and alpha-defensins
are encoded by adjacent genes: two peptide families with differing disulfide topology
share a common ancestry. Genomics. 1997;43:316-20.
5. Jarczak J, Kosciuczuk EM, Lisowski P, Strzalkowska N, Jozwik A, Horbanczuk J,
Krzyzewski J, Zwierzchowski L, Bagnicka E. Defensins: natural component of human
innate immunity. Hum Immunol. 2013;74:1069-79.
6. Ricci E, Malacrida S, Zanchetta M, Montagna M, Giaquinto C, De Rossi A. Role
of beta-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. J Acquir
Immune Defic Syndr. 2009;51:13-9.
7. Estrada-Aguirre JA, Osuna-Ramirez I, Prado Montes de Oca E, Ochoa-Ramirez
LA, Ramirez M, Magallon-Zazueta LG, Gonzalez-Beltran MS, Cazarez-Salazar SG,
Rangel-Villalobos H, Velarde-Felix JS. DEFB1 5'UTR polymorphisms modulate the
risk of HIV-1 infection in Mexican women. Curr HIV Res. 2014;12:220-6.
8. Freguja R, Gianesin K, Del Bianco P, Malacrida S, Rampon O, Zanchetta M,
Giaquinto C, De Rossi A. Polymorphisms of innate immunity genes influence disease
progression in HIV-1-infected children. AIDS. 2012;26:765-8.
9. Aguilar-Jimenez W, Zapata W, Rugeles MT. Differential expression of human beta
defensins in placenta and detection of allelic variants in the DEFB1 gene from HIV-1
positive mothers. Biomedica. 2011;31:44-54.
JU
ST
 AC
CE
PT
ED
10. Milanese M, Segat L, Pontillo A, Arraes LC, de Lima Filho JL, Crovella S.
DEFB1 gene polymorphisms and increased risk of HIV-1 infection in Brazilian
children. AIDS. 2006;20:1673-5.
11. Milanese M, Segat L, Crovella S. Transcriptional effect of DEFB1 gene 5'
untranslated region polymorphisms. Cancer Res. 2007;67:5997; author reply 
12. Sun CQ, Arnold R, Fernandez-Golarz C, Parrish AB, Almekinder T, He J, Ho
SM, Svoboda P, Pohl J, Marshall FF, Petros JA. Human beta-defensin-1, a potential
chromosome 8p tumor suppressor: control of transcription and induction of apoptosis
in renal cell carcinoma. Cancer Res. 2006;66:8542-9.
13. Flores Saiffe Farias A, Jaime Herrera Lopez E, Moreno Vazquez CJ, Li W, Prado
Montes de Oca E. Predicting functional regulatory SNPs in the human antimicrobial
peptide genes DEFB1 and CAMP in tuberculosis and HIV/AIDS. Comput Biol Chem.
2015;59 Pt A:117-25.
14. Segat L, Zupin L, Kim HY, Catamo E, Thea DM, Kankasa C, Aldrovandi GM,
Kuhn L, Crovella S. HLA-G 14 bp deletion/insertion polymorphism and mother-to-
child transmission of HIV. Tissue Antigens. 2014;83:161-7.
15. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to
perform population genetics analyses under Linux and Windows. Mol Ecol Resour.
2010;10:564-7.
16. RcoreTeam. R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/ 2015.
17. Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the
analysis of association studies. Bioinformatics. 2006;22:1928-9.
18. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power
analysis program for the social, behavioral, and biomedical sciences. Behav Res
Methods. 2007;39:175-91.
JU
ST
 AC
CE
PT
ED
19. Braida L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S. A single-
nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1
infection in Italian children. AIDS. 2004;18:1598-600.
20. Segat L, Milanese M, Boniotto M, Crovella S, Bernardon M, Costantini M,
Alberico S, Italian Group SHIViO, Gynecology. DEFB-1 genetic polymorphism
screening in HIV-1 positive pregnant women and their children. J Matern Fetal
Neonatal Med. 2006;19:13-6.
21. Segat L, Brandao LA, Guimaraes RL, Crovella S. Are defensin beta 1 gene
polymorphisms associated with HIV infection and virus replication? AIDS.
2009;23:647-9; author reply 9-50.
22. Schneider JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC. Human
defensins. J Mol Med (Berl). 2005;83:587-95.
23. Kalus AA, Fredericks LP, Hacker BM, Dommisch H, Presland RB, Kimball
JR, Dale BA. Association of a genetic polymorphism (-44 C/G SNP) in the human
DEFB1 gene with expression and inducibility of multiple beta-defensins in gingival
keratinocytes. BMC Oral Health. 2009;9:21.
24. Polesello V, Zupin L, Di Lenarda R, Biasotto M, Ottaviani G, Gobbo M, Cecco
L, Alberi G, Pozzato G, Crovella S, Segat L. Impact of DEFB1 gene regulatory
polymorphisms on hBD-1 salivary concentration. Arch Oral Biol. 2015;60:1054-8.
25. Nurjadi D, Herrmann E, Hinderberger I, Zanger P. Impaired beta-defensin
expression in human skin links DEFB1 promoter polymorphisms with persistent
Staphylococcus aureus nasal carriage. J Infect Dis. 2013;207:666-74.
26. Ryan LK, Diamond G. Modulation of Human beta-Defensin-1 Production by
Viruses. Viruses. 2017;9.
27. Corleis B, Lisanti AC, Korner C, Schiff AE, Rosenberg ES, Allen TM, Altfeld
M, Kwon DS. Early type I Interferon response induces upregulation of human beta-
defensin 1 during acute HIV-1 infection. PLoS One. 2017;12:e0173161.
JU
ST
AC
CE
PT
ED
28. Naslavsky MS, Crovella S, Lima Filho JL, Rocha CR. The sound of silence:
human beta-defensin-1 gene untranslated SNPs change the predicted mRNA
secondary structure in a length-dependent manner. Immunol Lett. 2010;129:53-5.
29. Baroncelli S, Ricci E, Andreotti M, Guidotti G, Germano P, Marazzi MC, Vella
S, Palombi L, De Rossi A, Giuliano M. Single-nucleotide polymorphisms in human
beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with
virologic parameters. AIDS. 2008;22:1515-7.
30. European Collaborative Study. Risk factors for mother-to-child transmission of
HIV-1. Lancet. 1992;339:1007-12.
31. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J,
Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human
immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women
and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402.
32. Kuhn L, Coutsoudis A, Trabattoni D, Archary D, Rossi T, Segat L, Clerici M, Crovella S.
Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A
influences susceptibility to HIV infection in infants born to HIV-positive mothers. Am J Clin Nutr.
2006;84:610-5.
Table 1: analysis of HIV-1 MTCT according to infant DEFB1polymorphismsallele,
genotype and haplotype frequencies comparing HIV-1 infected (HIV+) and HIV-1
exposed but not infected (HIV-) children.JU
ST
 AC
CE
PT
ED
CHILDREN HIV+a HIV-b HIV+a vs. HIV-b
n=85 n=246 p-value, O.R.c, 95% C.I.d
DEFB1
-52A>G
rs1799946
A 0.61 (103) 0.60 (293) reference
G 0.39 (67) 0.40 (199) p=0.86; ORc=0.96; CId=0.66-1.39
A/A 0.36 (31) 0.36 (89) reference
G/A 0.48 (41) 0.47 (115) p=1.00; ORc=1.02; CId=0.57-1.83
G/G 0.15 (13) 0.17 (42) p=0.85; ORc=0.89; CId=0.38-1.97
HWEe χ2=0.01; p=0.93 χ2=0.22; p=0.64
-44C>G
rs1800972
C 0.95 (161) 0.94 (462) reference
G 0.05 (9) 0.06 (30) p=0.85; ORc=0.86 CId=0.35-1.91
C/C 0.89 (76) 0.89 (219) reference
C/G 0.11 (9) 0.10 (24) p=0.83; ORc=1.08; CId=0.42-2.54
G/G 0.00 (0) 0.01 (3) Not calculable
HWEe χ2=0.27; p=0.61 χ2=5.39; p=0.02
-20A>G
rs11362
G 0.69 (117) 0.71 (348) reference
A 0.31 (53) 0.29 (144) p=0.63; ORc=1.09; CId=0.73-1.62
G/G 0.48 (41) 0.51 (125) reference
G/A 0.41 (35) 0.40 (98) p=.079; ORc=1.09 CId=0.62-1.90
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A/A 0.11 (9) 0.09 (23) p=0.66; ORc=1.19; CId=0.45-2.94
HWEe χ2=0.14; p=0.71 χ2=0.35; p=0.55
c.*87A>G
rs1800971
A 0.70 (119) 0.73 (361) reference
G 0.30 (51) 0.27 (131) p=0.43; ORc=1.18; CId=0.79-1.76
A/A 0.47 (40) 0.53 (131) reference
G/A 0.46 (39) 0.40 (99) p=0.36; ORc=1.29; CId=0.75-2.22
G/G 0.07 (6) 0.06 (16) p=0.79; ORc=1.23; CId=0.37-3.58
HWEe χ2=0.73; p=0.39 χ2=0.22; p=0.64
Haplotypes
ACGA 0.33 (56) 0.30 (147) reference
GCAA 0.25 (43) 0.25 (121) p=0.81; ORc=0.93; CId=0.57-1.52
ACGG 0.22 (38) 0.24 (117) p=0.55; ORc=0.85 CId=0.51-1.41
GCGA 0.02 (3) 0.09 (43) p=0.002; ORc=0.18; CId=0.03-0.61
others 0.18 (30) 0.13 (64) p=0.49; ORc=1.23; CId=0.69-2.16
a HIV+ = HIV-1 infected children
b HIV- = HIV-1 exposed but not infected children
c OR= odds ratio
d CI= confidence interval
e HWE = Hardy Weinberg equilibrium
Table 2: DEFB1 polymorphisms allele, genotype frequencies (and counts) in HIV-1
exposed but not infected children (HIV-) and HIV-1 infected children stratifying for
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timing of HIV-1 MTCT in intrauterine (IU), intrapartum (IP) and postpartum (PP)
groups.
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CHILDRENIUa IPb PPc HIV-d IUa vs HIV-d IPb vs HIV-d PPc vs HIV-d
n=22 n=25 n=38 n=246 p-value, O.R.e, 95%
C.I.f
p-value, O.R.e, 95%
C.I.f
p-value, O.R.e, 95%
C.I.f
DEFB1
-52A>G
rs1799946
A 0.57
(25)
0.56
(28)
0.66
(50)
0.60
(293)
reference reference reference
G 0.43
(19)
0.44
(22)
0.34
(26)
0.40
(199)
p=0.75; ORe=1.12;
CIf=0.57-2.18
p=0.65; ORe=1.16;
CIf=0.61-2.16
p=0.38; ORe=0.77;
CIf=0.44-1.30
A/A 0.41
(9)
0.28
(7)
0.39
(15)
0.36
(89)
reference reference reference
G/A 0.32
(7)
0.56
(14)
0.53
(20)
0.47
(115)
p=0.43; ORe=0.60;
CIf=0.18-1.90
p=0.49; ORe=1.54;
CIf=0.55-4.72
p=1.00; ORe=1.03;
CIf=0.47-2.30
G/G 0.27
(6)
0.16
(4)
0.08
(3)
0.17
(42)
p=0.57; ORe=1.41;
CIf=0.39-4.77
p=0.75; ORe=1.21;
CIf=0.25-5.07
p=0.27; ORe=0.43;
CIf=0.07-1.62
HWEg χ2=2.72
p=0.10
χ2=0.46
p=0.50
χ2=1.09
p=0.30
χ2=0.22
p=0.64
-44C>G
rs1800972
C 0.93
(41)
0.92
(46)
0.97
(74)
0.94
(462)
reference reference reference
G 0.07
(3)
0.08
(4)
0.03
(2)
0.06
(30)
p=0.75; ORe=1.13;
CIf=0.21-3.87
p=0.54; ORe=1.34;
CIf=0.33-4.04
p=0.29; ORe=0.42;
CIf=0.05-1.70
C/C 0.86
(19)
0.84
(21)
0.95
(36)
0.89
(219)
reference reference reference
C/G 0.14
(3)
0.16
(4)
0.05
(2)
0.10
(24)
p=0.48; ORe=1.44;
CIf=0.25-5.44
p=0.31; ORe=1.73;
CIf=0.40-5.77
p=0.55; ORe=0.51;
CIf=0.06-2.20
G/G 0.00
(0)
0.00
(0)
0.00
(0)
0.01 (3) p=1.00; ORe=0.00;
CIf=0.00-29.21
p=1.00; ORe=0.00;
CIf=0.00-26.33
p=1.00; ORe=0.00;
CIf=0.00-15.13
HWEg χ2=0.12
p=0.73
χ2=0.19
p=0.66
χ2=0.03
p=0.87
χ2=5.39
p=0.02
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-20A>G
rs11362
G 0.70
(31)
0.70
(35)
0.67
(51)
0.71
(348)
reference reference reference
A 0.30
(13)
0.30
(15)
0.33
(25)
0.29
(144)
p=1.00; ORe=1.01;
CIf=0.47-2.06
p=1.00; ORe=1.04;
CIf=0.51-2.02
p=0.50; ORe=1.18;
CIf=0.68-2.03
G/G 0.59
(13)
0.48
(12)
0.42
(16)
0.51
(125)
reference reference reference
G/A 0.23
(5)
0.44
(11)
0.50
(19)
0.40
(98)
p=0.22; ORe=0.49;
CIf=0.13-1.53
p=0.82; ORe=1.17;
CIf=0.45-3.03
p=0.27; ORe=1.51;
CIf=0.69-3.32
A/A 0.18
(4)
0.08
(2)
0.08
(3)
0.09
(23)
p=0.48; ORe=1.67;
CIf=0.36-6.05
p=1.00; ORe=0.91;
CIf=0.09-4.50
p=1.00; ORe=1.02;
CIf=0.18-4.00
HWEg χ2=4.54
p=0.03
χ2=0.06
p=0.81
χ2=0.67
p=0.41
χ2=0.35
p=0.55
c.*87A>G
rs1800971
A 0.57
(25)
0.82
(41)
0.70
(53)
0.73
(361)
reference reference reference
G 0.43
(19)
0.18
(9)
0.30
(23)
0.27
(131)
p=0.02; ORe=2.09;
CIf=1.05-4.10
p=0.23; ORe=0.60;
CIf=0.25-1.31
p=0.49; ORe=1.20;
CIf=0.67-2.08
A/A 0.27
(6)
0.64
(16)
0.47
(18)
0.53
(131)
reference reference reference
G/A 0.59
(13)
0.36
(9)
0.45
(17)
0.40
(99)
p=0.05; ORe=2.85;
CIf=0.97-9.49
p=0.53; ORe=0.74;
CIf=0.28-1.88
p=0.59; ORe=1.25;
CIf=0.57-2.71
G/G 0.14
(3)
0.00
(0)
0.08
(3)
0.06
(16)
p=0.08; ORe=4.04;
CIf=0.60-21.25
p=0.37; ORe=0.00;
CIf=0.00-2.39
p=0.81; ORe=1.36;
CIf=0.23-5.48
HWEg χ2=0.92
p=0.34
χ2=1.20
p=0.27
χ2=0.14
p=0.71
χ2=0.22
p=0.64
Haplotypes
ACGA 0.23
(10)
0.44
(22)
0.32
(24)
0.30
(147)
reference reference reference
GCAA 0.25
(11)
0.26
(13)
0.25
(19)
0.25
(121)
p=0.65; ORe=1.34;
CIf=0.50-3.64
p=0.47; ORe=0.72;
CIf=0.32-1.56
p=1.00; ORe=0.96;
CIf=0.47-1.93
ACGG
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0.32
(14)
0.08
(4)
0.26
(20)
0.24
(117)
p=0.20; ORe=1.76;
CIf=0.70-4.59
p=0.006; ORe=0.23;
CIf=0.06-0.70
p=1.00; ORe=1.05;
CIf=0.52-2.09
GCGA 0.00
(0)
0.02
(1)
0.03
(2)
0.09
(43)
p=0.12; ORe=0.00;
CIf=0.00-1.60
p=0.05; ORe=0.16;
CIf=0.00-1.02
p=0.11; ORe=0.29;
CIf=0.03-1.23
others 0.20
(9)
0.20
(10)
0.14
(11)
0.13
(64)
p=0.13; ORe=2.06;
CIf=0.70-5.95
p=1.00; ORe=1.04;
CIf=0.42-2.46
p=1.00; ORe=1.05;
CIf=0.44-2.39
a IU = intrauterine HIV-1 mother to child transmission 
b IP = intrapartum HIV-1 mother to child transmission 
c PP = postpartum HIV-1 mother to child transmission
d HIV- = HIV-1 exposed but not infected children
e OR= odds ratio
f CI= confidence interval
g HWE = Hardy Weinberg equilibrium
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